PT  - JOURNAL ARTICLE
AU  - JENNIFER MORITZ
AU  - THOMAS BAUERNHOFER
AU  - SEBASTIAN MANNWEILER
AU  - TANJA LANGSENLEHNER
AU  - KARL PUMMER
AU  - NADIA DANDACHI
AU  - MARTIN PICHLER
TI  - Evaluation of Blood-based Biomarkers for Prediction of Response in Carboplatin-treated Metastatic Castration-resistant Prostate Cancer Patients
AID  - 10.21873/invivo.12209
DP  - 2020 Nov 01
TA  - In Vivo
PG  - 3631--3638
VI  - 34
IP  - 6
4099  - http://iv.iiarjournals.org/content/34/6/3631.short
4100  - http://iv.iiarjournals.org/content/34/6/3631.full
SO  - In Vivo2020 Nov 01; 34
AB  - Background/Aim: Carboplatin-containing treatment regimens demonstrate moderate efficacy in metastatic castration-resistant prostate cancer (mCRPC). In this study, we retrospectively analyzed the efficacy of carboplatin in relation to blood-based parameters. Patients and Methods: A retrospective chart review was performed for 20 patients with mCRPC who received carboplatin in a single center. Results: Median overall survival was 3.8 months (95%CI=1.5-7.1), median progression-free survival was 1.7 months. We observed two partial remissions (PR, 10%), four stable diseases (SD, 20%) and 14 disease progressions (PD, 70%), resulting in a clinical benefit rate of 30%. A doubling of NSE (neurone specific enolase) values was associated with a 19% absolute higher response rate (95%CI=14-23, p=0.027). All other laboratory parameters failed as predictive markers of response to carboplatin. In univariate Cox regression analysis, only NSE was significantly associated with impaired PFS (HR=0.7, 95%CI=0.56-0.96, p=0.030). Conclusion: Carboplatin showed moderate efficacy against mCRPC in this unselected population of patients and NSE levels may help to predict the success of this treatment.